相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)
P. Pautier et al.
EUROPEAN JOURNAL OF CANCER (2020)
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study
Viktor Gruenwald et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials
Olivier Mir et al.
CLINICAL CANCER RESEARCH (2019)
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
Axel Le Cesne et al.
BMC CANCER (2019)
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schoffski et al.
LANCET (2016)
Pazopanib vs pazopanib plus gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO.
Hans -Joachim Schmoll et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Study NCT01692496.
Claudia Maria Valverde et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
Ruth Plummer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)
Patricia Pautier et al.
ONCOLOGIST (2012)
Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
Daniel Braas et al.
CANCER DISCOVERY (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas
Robert G. Maki et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
JT Hartmann et al.
INVESTIGATIONAL NEW DRUGS (2006)
Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOC) Study
KY Look et al.
GYNECOLOGIC ONCOLOGY (2004)
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
L Svancarova et al.
EUROPEAN JOURNAL OF CANCER (2002)
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation
SR Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
